Skip to main content
. 2022 Feb 11;16(5):697–705. doi: 10.5009/gnl210365

Table 1.

Baseline Characteristics of the Patients

Variable 14-Day BQT (n=102) 14-Day MIT (n=99) p-value* 14-Day CTT (n=581)
Age, yr 56.6±11.1 56.7±11.3 0.905 55.3±12.6
Male sex 41 (40.2) 42 (42.9) 0.703 332 (57.1)
Mean BMI, kg/m2 24.3 24.6 0.263 25.4
Diabetes 18/97 (18.6) 18/97 (18.6) >0.999 79/563 (14.0)
Hypertension 18/99 (18.2) 14/97 (14.4) 0.478 168/563 (29.8)
History of peptic ulcer 12 (11.7) 13 (13.1) 0.809 118/563 (20.9)
Smoking 11/89 (12.4) 17/89 (19.1) 0.051 153/479 (31.9)
Alcohol 17/76 (22.4) 26/82 (31.7) 0.247 230/479 (48.0)
Diagnosis 0.429
Gastritis 51 (50.0) 41 (41.4) 244 (42.0)
Peptic ulcer 46 (45.1) 53 (53.5) 302 (52.0)
Gastric cancer 2 (2.0) 1 (1.0) 17 (2.9)
Gastric adenoma 2 (2.0) 4 (4.1) 15 (2.6)
MALT lymphoma 1 (0.9) 0 3 (0.5)
Significant point mutation
A2142G 3 (2.9) 3 (3.0) >0.999
A2143G 95 (93.1) 93 (93.9) 0.290
A2142C 2 (2.1) 1 (1.0) 0.619
A2143C 2 (2.1) 1 (1.0) 0.621
A2144G 34 (35.1) 36 (37.9) 0.795

Data are presented as mean±SD, number (%), or number/number (%).

BQT, bismuth-based quadruple therapy; MIT, metronidazole-intensified triple therapy; CTT, clarithromycin-based triple therapy; BMI, body mass index; MALT, mucosa-associated lymphoid tissue.

*p-value indicates comparison between the BQT and MIT; The sum of proportion is not 100% because of overlapping among point mutations.